Sysmex (OTCMKTS:SSMXY) Posts Earnings Results, Misses Estimates By $0.02 EPS

by · The Cerbat Gem

Sysmex (OTCMKTS:SSMXY – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02), Zacks reports. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Sysmex updated its FY 2026 guidance to 0.370-0.370 EPS.

Sysmex Stock Down 4.0%

Shares of OTCMKTS SSMXY traded down $0.34 during mid-day trading on Thursday, hitting $8.12. The company had a trading volume of 553,102 shares, compared to its average volume of 267,723. The company has a market capitalization of $5.11 billion, a PE ratio of 16.92 and a beta of 1.10. The firm has a 50-day simple moving average of $8.75 and a two-hundred day simple moving average of $9.42. The company has a current ratio of 3.33, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. Sysmex has a one year low of $8.12 and a one year high of $18.10.

Analyst Upgrades and Downgrades

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Check Out Our Latest Stock Analysis on SSMXY

Sysmex Company Profile

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

Read More